Kambiz Karimi
Internal Medicine · Newport Beach, CANPI 1720061823
Payments from drug & device makers
Across 275 payments — averaging $62.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$12K
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$734
- Almatica Pharma LLC$581
- Eisai Inc.$291
- Alkermes, Inc.$247
- plus $1K from 14 others
What the payments were for
- Consulting fees$1,6209%
- Speaking & faculty fees$9,00052%
- Travel & lodging$1,6349%
- Food & beverage$5,03629%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 52 | $11,755 |
| AbbVie(2 entities) | 75 | $2,625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $734 |
| Almatica Pharma LLC | 23 | $581 |
| Eisai Inc. | 23 | $291 |
| Alkermes, Inc. | 11 | $247 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $205 |
| Merck | 10 | $176 |
| Gilead | 6 | $139 |
| Axsome Therapeutics, Inc. | 4 | $102 |
| Orexo US, Inc. | 4 | $86 |
| Pfizer | 3 | $69 |
| Adlon Therapeutics L.p. | 3 | $54 |
| MDD US Operations, LLC | 4 | $54 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| USWM, LLC | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $17 |
| Masimo Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,294 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $21,758 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 89 | $6,312 |
| Acamprosate Calcium | 12 | $2,950 |
| Quetiapine Fumarate | 66 | $1,497 |
| Gabapentin | 74 | $856 |
| Lactulose | 13 | $782 |
| Naltrexone Hcl | 14 | $551 |
| Buprenorphine Hcl | 27 | $526 |
| Mirtazapine | 29 | $357 |
| Bupropion Hcl SrBupropion Hcl | 12 | $351 |
| Olanzapine | 12 | $238 |
| Chlordiazepoxide Hcl | 12 | $185 |
| Escitalopram Oxalate | 13 | $173 |
| Sertraline Hcl | 21 | $145 |
| Pregabalin | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $11,755 | $21,75840 claims |
| Almatica Pharma LLCSertraline Hcl | $581 | $14521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Newport Beach
- Ryan KleinNewport Beach$5M
- Tung NgoNewport Beach$4.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.